admin In a world first, the vaccine developed by Johnson and Johnson that requires only a single dose as opposed to the other competitors in the market that require 2 doses for building immunity has been deemed as safe and effective by the US Food and Drug Administration.
According to the documents produced, the FDA is convinced that the vaccine is safe for use. The expert panel met in order to look deeply into the efficacy and use of the vaccine. It is all set to meet in a day or two to finally decide if the vaccine is to be authorized for emergency use in the United States.
According to the tests conducted, the efficacy of the vaccine has been found to be about 66% and it worked against the various variants that have started surfacing in different parts of the world. the trial for the single dose Johnson and Johnson vaccine was done throughout the world and involved more than 44,000 individuals.
The effectiveness of the vaccine however varied from one place to another. In the United States, it was found to be around 72%, 66% in Latin America and the lowest in South Africa at around 57%. The overall effectiveness in curbing the spread however was around 85%.
According to the tests and experimentation and the data received, the vaccine takes around 14 days to build the immunity of an individual. The other vaccines in the world including Pfizer, Moderna, AstraZeneca have better effectiveness but require two doses before an individual gets protection or develops an immunity.
During the trial of the vaccine, only three out of 44,000 individuals developed severe response to the vaccination. Therefore, the FDA feels that the analysis that has been conducted does not raise a lot of questions and in particular the question of safety.
All the data has been released now by J&J given that it has applied for emergency approval in the United States. Prior to this, only the efficacy rates had been provided. It remains to be seen whether or not this becomes the third vaccine to be approved in the United States.
Magazine 
